The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

A method, comprising the steps of providing a sample containing contaminating nucleoside diphosphates and/or nucleoside triphosphates, such as ATP and/or ATP analogues including deoxyribonucleoside triphosphates; reducing the amount of the contaminating nucleoside diphosphates and/or nucleoside triphosphates in the sample with an apyrase enzyme, wherein said apyrase enzyme is a Shigella flexneri apyrase; and performing an analysis of the sample, wherein said analysis comprises an assay that would have been affected by the contaminating nucleoside diphosphates and/or nucleoside triphosphates had they not been reduced in the reduction step.

The present invention relates to a chimeric enzyme comprising or consisting of at least one catalytic domain of a capping enzyme and at least one RNA-binding domain of a protein-RNA tethering system as well as its application for the production of an RNA molecule with a 5′-terminal cap.

Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.

The present invention relates to improvement of epithelial or endothelial barrier function by increasing a level of myotonic dystrophy kinase-related Cdc42-binding kinases a (MRCKalpha) in one or more cells in the barrier.

The present invention relates to a chimeric enzyme comprising or consisting of at least one catalytic domain of a capping enzyme and at least one RNA-binding domain of a protein-RNA tethering system as well as its application for the production of an RNA molecule with a 5-terminal cap.

The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.

Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.

The present invention relates to a pharmaceutical composition for treating STK11-mutation cancer, containing, as an active ingredient, a material inhibiting a sodium-potassium transport function of Na.sup.+K.sup.+ ATPase (ATP1A1); an anticancer drug containing the composition as an active ingredient; and a method for screening STK11-mutation cancer therapeutic agent. It was first established that, of cancer cells in which various gene mutations are confirmed, an STK11-mutation cancer cell line, which is confirmed at high frequency, was treated with cardiac glycosides as a material inhibiting a sodium-potassium transport function of Na.sup.+K.sup.+ ATPase (ATP1A1), to significantly inhibit the growth of cancer cells. Therefore, the material inhibiting a sodium-potassium transport function of Na.sup.+K.sup.+ ATPase (ATP1A1) can be a target for treating SK11-mutation-derived cancer.

The present disclosure features compositions and methods for producing one or more isoprenoid compounds, such as gamma-ambryl acetate (GAA), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of an isoprenoid biosynthetic pathway, such as a pathway for making GAA. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of an isoprenoid biosynthetic pathway, such as an enzyme capable of converting manooloxy to GAA. The host cell may be cultured in a medium, for example, in the presence of an agent that regulates expression of the one or more enzymes. The host cell may be incubated for a time sufficient to allow for production of an isoprenoid compound, such as GAA. The isoprenoid compound may then be separated from the host cell or from the medium.